Growth Metrics

Soleno Therapeutics (SLNO) EBIT Margin (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed EBIT Margin for 6 consecutive years, with 43.15% as the latest value for Q4 2025.

  • For Q4 2025, EBIT Margin changed N/A year-over-year to 43.15%; the TTM value through Dec 2025 reached 4.98%, changed N/A, while the annual FY2025 figure was 4.94%, 8123791.0% down from the prior year.
  • EBIT Margin hit 43.15% in Q4 2025 for Soleno Therapeutics, up from 33.48% in the prior quarter.
  • Across five years, EBIT Margin topped out at 3360.98% in Q1 2025 and bottomed at 19.98% in Q2 2025.